Kuva Labs to Acquire Lisata Therapeutics at $4 Cash Offer
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 21 2026
0mins
Should l Buy LSTA?
Lisata Therapeutics entered into a binding term sheet to be acquired by Kuva Labs. Pursuant to the terms and conditions of the term sheet, Kuva and Lisata agreed to negotiate in good faith and enter into a customary purchase agreement to consummate a negotiated acquisition of Lisata by Kuva whereby Kuva will commence a tender offer to purchase all of the outstanding shares of common stock of Lisata at a price of $4.00 per share in cash. Additionally, Lisata stockholders will be entitled to receive two non-tradeable contingent value rights, payable as follows: $1.00 per share, in cash, within 12 months of the date on which rights to certepetide in the Greater China region revert to Lisata from Qilu Pharmaceutical; and $1.00 per share, in cash, upon the filing of an NDA or similar registration document by Kuva for approval to commercialize certepetide in any indication in any jurisdiction. The term sheet and transaction contemplated thereby have been unanimously approved by the boards of directors of Lisata and Kuva. The Company and Kuva expect to enter into a definitive purchase agreement prior to February 27. The $4.00 per share cash offer price represents an approximate 85% premium and, including both CVRs, an approximate 180% premium to Lisata's most recent closing stock price and reflects the strategic value of the Company's clinical pipeline and the breakthrough potential of its lead product candidate, certepetide. In November 2024, Kuva had licensed Lisata's iRGD cyclic peptide product candidate, certepetide, as a targeting and enhanced delivery agent to be used with Kuva's NanoMark platform technology and has begun development of a potentially new class of advanced magnetic resonance imaging agents that could enable the safe, non-invasive and unambiguous detection of solid tumor cancers.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LSTA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LSTA
About LSTA
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company engaged in the discovery, development and commercialization of therapies for the treatment of advanced solid tumors and other major diseases. The Company’s cyclic peptide product candidate, certepetide, is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Certepetide actuates this active transport system in a tumor-specific manner, resulting in systemically co-administered anti-cancer drugs penetrating and accumulating in the tumor, while normal tissues are expected to remain unaffected. The Company’s investigational drug candidate from the CendR Platform, certepetide, holds broader potential to be combined as a co-administration treatment with an array of anti-cancer and diagnostic agents to benefit solid tumor cancer patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
Investor Rights Law Firm Investigates Sila Realty and Lisata Therapeutics
- Legal Investigation: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. and Lisata Therapeutics, Inc. to assess potential violations of federal securities laws in their transactions with Blue Owl Real Estate Capital and Kuva Labs, which may impact shareholder rights.
- Transaction Details: The sale price for Sila Realty is set at $30.38 per share, while Lisata's deal includes $4.00 per share plus two non-tradeable contingent value rights, terms that could limit superior competing offers and affect potential shareholder returns.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options, promising to provide legal services without upfront costs, aiming to secure increased consideration and additional disclosures for affected investors.
- Commitment to Legal Services: The firm represents investors globally, focusing on cases of securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating their expertise in protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Lisata Therapeutics, Inc. and Smithfield Foods, Inc., with Lisata shareholders expected to receive $4.00 per share in cash and potential contingent value rights, providing additional revenue opportunities for shareholders.
- Independent Bank Merger: In the merger between Independent Bank Corporation and HCB Financial Corp., HCB shareholders are expected to receive 1.5900 shares of Independent common stock and $17.51 in cash per share, which will enhance Independent Bank's market position.
- Sila Realty Sale: In the transaction involving Sila Realty Trust, Inc. and Sunshine Ultimate Parent LLC, Sila Realty shareholders are expected to receive $30.38 in cash per share, delivering substantial cash returns to shareholders.
- Commitment to Legal Services: Monteverde Law Firm is recognized for its successful track record in securities class actions, emphasizing its ability to secure compensation for shareholders, thereby enhancing its competitive edge in the legal services market.
See More
Investigation into Lisata's Transaction with Kuva Labs for Possible Fiduciary Breaches
- Transaction Details: Lisata's agreement to provide stockholders with $5.00 per share in cash plus a contingent value right for an additional $1.00 per share upon FDA filing raises concerns about long-term shareholder interests and potential undervaluation.
- Board Investigation: Ademi LLP is probing whether Lisata's board fulfilled its fiduciary duties to all shareholders, particularly given the transaction's restrictive clauses on competing bids, which could have significant legal implications.
- Insider Benefits: The substantial benefits for Lisata insiders as part of the change of control arrangements raise questions about prioritizing personal interests over those of shareholders, potentially leading to shareholder dissatisfaction and unrest.
- Legal Risks: The significant penalties imposed on Lisata for accepting competing offers may expose the company to legal challenges, and Ademi LLP's investigation will assess whether this behavior violates shareholder rights, impacting the company's governance structure moving forward.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Lisata Therapeutics to be Acquired by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics has entered into a definitive acquisition agreement with Kuva Labs, which will purchase all outstanding shares at $5.00 each in cash, indicating strong recognition of Lisata's future potential.
- Contingent Value Rights: Each share will come with a contingent value right (CVR) that entitles holders to an additional $1.00 per share if a New Drug Application related to the candidate certepetide is accepted by the FDA within seven years, showcasing an incentive mechanism for successful R&D.
- Transaction Timeline: The transaction is expected to close in the second quarter of 2026, after which Lisata will become part of Kuva Labs and will be delisted from the Nasdaq Capital Market, marking a significant strategic restructuring for the company.
- Stock Price Fluctuation: Lisata closed at $4.18 last Friday, down 1.18%, but surged to $4.99 in after-hours trading, a 19.38% increase, reflecting the market's positive reaction to the acquisition news.
See More
Investigations into Multiple Biotech Company Mergers
- Esperion Acquisition Investigation: Esperion Therapeutics is set to be acquired by ARCHIMED for $3.16 per share in cash, with potential contingent milestone payments of up to $100 million, raising concerns about whether the board breached fiduciary duties by failing to ensure fair pricing for shareholders.
- Sila Realty Acquisition Scrutiny: Sila Realty Trust will be acquired by Blue Owl Capital for $30.38 per share in an all-cash deal valued at approximately $2.4 billion, with investigations questioning whether the board adequately protected shareholder interests during the transaction process, potentially affecting fair value.
- Lisata Therapeutics Merger Investigation: Lisata Therapeutics is being acquired by Kuva Labs for $4.00 per share in cash, along with two non-tradeable rights, prompting investigations into whether the board conducted a fair process, which could impact shareholder benefits.
- SkyWater Technology Acquisition Review: SkyWater is to be acquired by IonQ for $35.00 per share in a cash-and-stock deal valued at around $1.8 billion, with investigations focusing on whether the board fulfilled its fiduciary duties, particularly as the deal price is below the company's 52-week high of $36.27.
See More
Investor Rights Law Firm Investigates Sila Realty and Lisata Therapeutics
- Legal Investigation: Halper Sadeh LLC is investigating Sila Realty Trust, Inc. and Lisata Therapeutics, Inc. to assess potential violations of federal securities laws in their transactions with Blue Owl Real Estate Capital and Kuva Labs, which may impact shareholder rights.
- Transaction Details: The sale price for Sila Realty is set at $30.38 per share, while Lisata's deal includes $4.00 per share plus two non-tradeable contingent value rights, terms that could limit superior competing offers and affect potential shareholder returns.
- Shareholder Rights Protection: Halper Sadeh LLC encourages shareholders to contact them to discuss their rights and options, promising to provide legal services without upfront costs, aiming to secure increased consideration and additional disclosures for affected investors.
- Commitment to Legal Services: The firm represents investors globally, focusing on cases of securities fraud and corporate misconduct, having successfully implemented corporate reforms and recovered millions for defrauded investors, demonstrating their expertise in protecting investor rights.
See More
Monteverde Law Firm Investigates Multiple Acquisition Cases
- Shareholder Compensation Investigation: Monteverde Law Firm is investigating the transaction between Lisata Therapeutics, Inc. and Smithfield Foods, Inc., with Lisata shareholders expected to receive $4.00 per share in cash and potential contingent value rights, providing additional revenue opportunities for shareholders.
- Independent Bank Merger: In the merger between Independent Bank Corporation and HCB Financial Corp., HCB shareholders are expected to receive 1.5900 shares of Independent common stock and $17.51 in cash per share, which will enhance Independent Bank's market position.
- Sila Realty Sale: In the transaction involving Sila Realty Trust, Inc. and Sunshine Ultimate Parent LLC, Sila Realty shareholders are expected to receive $30.38 in cash per share, delivering substantial cash returns to shareholders.
- Commitment to Legal Services: Monteverde Law Firm is recognized for its successful track record in securities class actions, emphasizing its ability to secure compensation for shareholders, thereby enhancing its competitive edge in the legal services market.
See More
Investigation into Lisata's Transaction with Kuva Labs for Possible Fiduciary Breaches
- Transaction Details: Lisata's agreement to provide stockholders with $5.00 per share in cash plus a contingent value right for an additional $1.00 per share upon FDA filing raises concerns about long-term shareholder interests and potential undervaluation.
- Board Investigation: Ademi LLP is probing whether Lisata's board fulfilled its fiduciary duties to all shareholders, particularly given the transaction's restrictive clauses on competing bids, which could have significant legal implications.
- Insider Benefits: The substantial benefits for Lisata insiders as part of the change of control arrangements raise questions about prioritizing personal interests over those of shareholders, potentially leading to shareholder dissatisfaction and unrest.
- Legal Risks: The significant penalties imposed on Lisata for accepting competing offers may expose the company to legal challenges, and Ademi LLP's investigation will assess whether this behavior violates shareholder rights, impacting the company's governance structure moving forward.
See More
Lisata Therapeutics to be Taken Private by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics Inc has agreed to be taken private by Kuva Labs, offering shareholders $5.00 per share along with a $1.00 contingent value right per share, indicating recognition of the company's future potential.
- Significant Stock Surge: Following the acquisition announcement, Lisata Therapeutics' shares rose 20.3% in pre-market trading to $5.03, reflecting positive market reaction and increased investor confidence in the deal.
- Impact of Privatization: The acquisition will result in Lisata Therapeutics delisting from public markets, potentially providing the company with greater flexibility to focus on long-term strategic goals while mitigating the impact of market volatility on its operations.
- Market Dynamics Shift: The announcement of this deal has sparked interest in other related stocks, demonstrating investor enthusiasm for M&A activity in the biotech sector, which may influence future investment decisions and market trends.
See More
Lisata Therapeutics to be Acquired by Kuva Labs
- Acquisition Agreement: Lisata Therapeutics has entered into a definitive acquisition agreement with Kuva Labs, which will purchase all outstanding shares at $5.00 each in cash, indicating strong recognition of Lisata's future potential.
- Contingent Value Rights: Each share will come with a contingent value right (CVR) that entitles holders to an additional $1.00 per share if a New Drug Application related to the candidate certepetide is accepted by the FDA within seven years, showcasing an incentive mechanism for successful R&D.
- Transaction Timeline: The transaction is expected to close in the second quarter of 2026, after which Lisata will become part of Kuva Labs and will be delisted from the Nasdaq Capital Market, marking a significant strategic restructuring for the company.
- Stock Price Fluctuation: Lisata closed at $4.18 last Friday, down 1.18%, but surged to $4.99 in after-hours trading, a 19.38% increase, reflecting the market's positive reaction to the acquisition news.
See More
